<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368492">
  <stage>Registered</stage>
  <submitdate>6/05/2015</submitdate>
  <approvaldate>22/05/2015</approvaldate>
  <actrnumber>ACTRN12615000517572</actrnumber>
  <trial_identification>
    <studytitle>Comparison of two dialysis modes: nocturnal haemodialysis (NHD) and haemodiafiltration (HDF) in  haemodialysis patients.</studytitle>
    <scientifictitle>The effect of nocturnal haemodialysis (NHD) and haemodiafiltration (HDF) on the biochemical profile of haemodialysis patients.</scientifictitle>
    <utrn>U1111-1169-9356</utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>haemodialysis</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>2X2 Crossover study - comparison of 2 different dialysis membranes plus comparison of NHD vs HDF.

Baseline status (prior to first study treatment): Nocturnal haemodialysis (8 hour sessions, 3.5x per week) - performed at home, using Fresenius Cordiax dialysers.

Randomisation 1: randomised to either remain on the Fresenius Cordiax dialysers OR to change to Nipro Elisio dialysers - of similar surface area.

Randomisation 2: enter cross-over trial of either NHD followed by HDF or vice versa; both with a 2 week washout (regular nocturnal HD) in between.
The study session will be the last dialysis session of each 2-week study period (NHD and HDF): for NHD this study session will be performed in the Home training unit.
Trial comparator: Haemodiafiltration (4 hour sessions, 3x per week) - performed in the Home Dialysis Training Unit under nurse supervision.
Study periods are 2 weeks each, with the last session in the 2-week period being the tested session. There is a 2 week washout between the two periods, wherein patients return to their baseline (NHD) treatment pattern.

For the 2-week NHD study period, patients will have 3x per week dialysis (rather than 3.5x) to allow closer comparison.


</interventions>
    <comparator>Nocturnal haemodialysis - 8 hour, overnight dialysis sessions at 250 ml/min blood flow and 300 ml/min dialysate flow - 3 - 3.5 times per week. Performed without supervision at home; except for the final study session which will be performed in the Dialysis Unit.

The patients will usually be using the Fresenius membrane prior to the study. The Nipro Elisio dialyser will be considered the comparator membrane.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>serum biochemical parameters of dialysis adequacy (urea, phosphate, B2microglobulin, retinol binding protein, fetuin, FGF-23, alpha-1 microglobulin) as a composite outcome</outcome>
      <timepoint>Biochemical assessment at baseline and at the end of 2 weeks of each treatment option.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>dialysate based assessment of removal of urea and phosphate</outcome>
      <timepoint>baseline and at the end of each 2-week treatment phase.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>cardiovascular stability - as assessed by blood pressure during dialysis.</outcome>
      <timepoint>during the last dialysis session of each 2-week treatment phase.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>existing nocturnal haemodialysis patients
have been stable on NHD for at least 3 months
permanent vascular access</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>planned transplant
not able to provide consent
not able to adhere to protocol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>recruitment from existing nocturnal HD cohort
random allocation to membrane type and cross-over sequence using computer generated randomisation program by team member not involved in recruitment.
(2x2 trial - membrane type as well as NHD vs HDF sequence)</concealment>
    <sequence>computer generated random allocation protocol by third party</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>2 x 2  also assessing membrane type </designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>group comparisons of biochemical endpoints.
This is a pilot study. 
The only other published study involved 8 patients examined over a single dialysis.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2015</anticipatedstartdate>
    <actualstartdate>1/02/2016</actualstartdate>
    <anticipatedenddate>30/06/2016</anticipatedenddate>
    <actualenddate>30/06/2016</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>25/11/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof Peter Kerr</primarysponsorname>
    <primarysponsoraddress>Dept of Nephrology
Monash Medical Centre
246 Clayton Rd
Clayton, Vic, 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Nipro Japan</fundingname>
      <fundingaddress>Nipro - Global Business Division
3-9-3 Honjo-Nishi Kita-Ku 
Osaka 531-8510 
JAPAN </fundingaddress>
      <fundingcountry>Japan</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Monash Medical Centre Department of Nephrology</fundingname>
      <fundingaddress>Monash Medical Centre
246 Clayton Rd
Clayton, 3168
Vic, Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>A/Prof Kevan Polkinghorne</sponsorname>
      <sponsoraddress>Dept of Nephrology
Monash Medical Centre
246 Clayton Rd
Clayton, Vic, 3168</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study examines the biochemical effects of two different dialysis modes. Surprisingly, this has not been well covered in the literature, despite both modes having been practiced for 20+ years.
As a secondary feature it also compares two different dialysis membranes utilised in these dialysis modes.</summary>
    <trialwebsite>nil</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash Health</ethicname>
      <ethicaddress>Monash Medical Centre
246 Clayton Rd
Clayton, 3168
Victoria</ethicaddress>
      <ethicapprovaldate>10/04/2015</ethicapprovaldate>
      <hrec>15011L</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Peter Kerr</name>
      <address>Dept of Nephrology
Monash Medical Centre
246 Clayton Rd,
Clayton, 3168, Vic</address>
      <phone>+61 3 9594-3524</phone>
      <fax>+61 3 9594 6530</fax>
      <email>peter.kerr@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Peter Kerr</name>
      <address>Dept of Nephrology
Monash Medical Centre
246 Clayton Rd,
Clayton, 3168, Vic</address>
      <phone>+61 3 9594 3524</phone>
      <fax />
      <email>peter.kerr@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Peter Kerr</name>
      <address>Dept of Nephrology
Monash Medical Centre
246 Clayton Rd,
Clayton, 3168, Vic</address>
      <phone>+61 3 9594 3524</phone>
      <fax />
      <email>peter.kerr@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Peter Kerr</name>
      <address>Dept of Nephrology
Monash Medical Centre
246 Clayton Rd,
Clayton, 3168, Vic</address>
      <phone>+61 3 9594 3524</phone>
      <fax />
      <email>peter.kerr@monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>